Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. - Wikidata - wikimedia - TriplyDB

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

http://www.wikidata.org/entity/Q52907227

about

Cancer classification using the Immunoscore: a worldwide task force Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test Towards tumor immunodiagnostics Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer The role of preoperative systemic treatment in patients with breast cancer Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It Breast cancer survival among young women: a review of the role of modifiable lifestyle factors The fate of chemoresistance in triple negative breast cancer (TNBC)Advances in immunotherapy for treatment of lung cancer Relevance of tumor-infiltrating lymphocytes in breast cancer Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment Tumor microenvironment and the pathologist: looking at what we just see Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis An immunologic portrait of cancer Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Clinical significance of tumor-infiltrating lymphocytes in breast cancer Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Immune DNA signature of T-cell infiltration in breast tumor exomes.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter?Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer.HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer

P2860

Q21245495-AEA4F6B1-8008-4084-B1D7-619DBBDE5754 Q21261272-6CC2D622-F201-4F0F-8894-98B61D439A4C Q26738691-E8594B09-277F-41B7-B636-7E90C3464CB7 Q26739445-6987130D-9B9F-4F31-B1A7-AE5E7C60123B Q26745444-2FFF8E61-BA3E-4132-8FA3-21E0075CBEDC Q26745446-9A3E2A66-4260-4401-8F46-7BC95739370B Q26746034-FED8B662-59AB-4D6B-9AB3-1B0FBB04C499 Q26747792-568790CD-6D84-44E5-8358-F53237B6CB1F Q26748691-764A9AAB-AB4C-4A67-9BF7-26BE487AFA41 Q26752780-426E0300-E0C0-4A23-AF55-253322AB15DB Q26766205-DA18CEF7-1AA7-4A18-8D56-212DFB60CF1D Q26775232-795F582F-84B2-4BAE-99A7-0637AA78986E Q26778790-39BADB5B-D249-41FB-A735-776A5564A299 Q26795598-0389FB97-3105-4293-BD1A-3E6F2C408358 Q26798074-EA20AED5-B736-483A-A53E-B0C18A8FB9C0 Q26799117-E051F3C8-8A20-4A95-99C1-489A249A234F Q26799123-9EB77A85-C179-463E-BBA4-4CA35887FF63 Q26866052-51D28AD2-6DE4-44A4-9395-1D31BFBC359B Q27022482-BF75B2CF-9755-467C-8B70-AC92FC9AD98C Q27028000-8932150F-D251-4655-ADC2-9081C6146F02 Q27311085-0F5D8F94-5139-44CF-B2B6-EA5286C62DB7 Q28070214-6528F342-01D7-4E79-8431-993D51176E68 Q28077815-CA7BA065-E491-4FE3-B327-206C9D69A1BF Q28554412-6D77E1C8-E40E-4F9C-9C91-101A59E28873 Q30245184-07543EA3-A57C-409A-B3E9-FFBE6A622D2C Q30253017-45F8F225-E440-4C2C-9D80-C00378BF205E Q30276247-246F06E7-C368-4010-B0E9-53115B8C4D49 Q30276874-C7EAD46A-1097-4820-B51C-33F401EDC5C4 Q30318240-B666786B-5E66-4A9E-BF50-673C53E9BEA8 Q30377226-83E369E2-E522-4D84-8440-37E6586F8581 Q30543788-99CEEEB2-724F-4FF0-9F41-116ABA89A5A3 Q30857631-3BEAC027-6108-44BC-8537-B5CB3C68A0AA Q31053828-7AB65D02-3544-41B5-8512-5F6C8D6BC6BC Q31102636-CCDA770A-B2D5-475E-B23B-6895BB7B1E09 Q33441772-B3ACC9A3-6243-49B1-B61F-D3AF3224E43A Q33576409-8AD295A7-C12C-4A6A-B7CA-CE12081137B2 Q33591683-31DF45D8-69A8-4F72-B1E9-51E9F5EB41B7 Q33595267-228EB33E-7574-47F2-B417-AE1CD8D9511D Q33611598-73FE8199-3AF5-49F0-AB25-2A00A7F669E0 Q33613602-B15D2444-020E-47F8-A717-BA19856526B2

P2860

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

http://www.wikidata.org/entity/Q52907227

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Tumor-associated lymphocytes a ...... chemotherapy in breast cancer.

@en

Tumor-associated lymphocytes a ...... chemotherapy in breast cancer.

@nl

type

label

Tumor-associated lymphocytes a ...... chemotherapy in breast cancer.

@en

Tumor-associated lymphocytes a ...... chemotherapy in breast cancer.

@nl

prefLabel

Tumor-associated lymphocytes a ...... chemotherapy in breast cancer.

@en

Tumor-associated lymphocytes a ...... chemotherapy in breast cancer.

@nl

P1433

Q52907227-0E8607EB-4373-4547-BB2F-581517434B00

P1476

Q52907227-3C2B289F-0567-4976-AC4C-A18BEBE8ED08

P2093

Q52907227-0739AEEA-013C-4898-877E-E8F4A63E2B1F

Q52907227-15DD376A-4939-4D6B-86D0-5873FF2BAA47

Q52907227-38361F60-6D93-4379-B941-6E500E8E13EC

Q52907227-4D1EA61A-B604-4807-A9FF-4E4F1D8CE389

Q52907227-4E4E0476-4863-4911-AE19-2CA9B9CDC76C

Q52907227-4EE41E92-A2A2-413E-A5C1-C623038B5E0E

Q52907227-64878B60-158E-4EFE-AD1F-220E1B90925D

Q52907227-657C35D9-EBFD-4454-9B4F-263A4DBB5DE5

Q52907227-AD81B858-848C-42F2-BD1A-72D91807AB29

Q52907227-CE7B43C4-CD4E-486D-80AD-86DE28BEFC59

P304

Q52907227-1BB8EBAE-8D19-46F9-9133-7EA59747B38E

P31

Q52907227-A99AD3BF-35A6-4D09-9E1E-7BFCD117A44C

P356

Q52907227-DABDDA8F-6B0D-484D-AD3A-36F3313DF8EE

P407

Q52907227-9E41BD87-D31F-4DC1-9737-B87277A591EF

P433

Q52907227-E825FFA5-AB4B-4E32-82CC-D8C11F2AC1DD

P478

Q52907227-474B766E-384C-4525-A3E5-EE23C0699A19

P50

Q52907227-61D449C8-359B-480A-9E7C-83AB623CB6F9

Q52907227-A6315C5A-265C-47D4-AF6D-1BBCE4329BE4

Q52907227-E12BF200-F112-42CA-B7C3-E8C61040F28F

Q52907227-acd6fb32-49f4-0c88-eaca-40545ad1cbe8

P577

Q52907227-DA238FC8-52B9-4055-AEC9-4C089DB17B3C

P5875

Q52907227-F2F873F9-D499-4EF6-BA64-6C0D5E59598F

P698

Q52907227-43268A8B-FCAA-4844-BC57-DC906B044C36

P921

Q52907227-1E0942C6-5598-4D4C-81A7-25674C2B56B6

P356

JCO.2009.23.7370

P1433

Journal of Clinical Oncology

P1476

Tumor-associated lymphocytes a ...... chemotherapy in breast cancer.

@en

P2093

Aurelia Noske

http://www.w3.org/2001/XMLSchema#string

Berit Maria Müller

http://www.w3.org/2001/XMLSchema#string

Christian von Törne

http://www.w3.org/2001/XMLSchema#string

Christine Solbach

http://www.w3.org/2001/XMLSchema#string

Claus Hanusch

http://www.w3.org/2001/XMLSchema#string

Gunter von Minckwitz

http://www.w3.org/2001/XMLSchema#string

Iris Schrader

http://www.w3.org/2001/XMLSchema#string

Knut Engels

http://www.w3.org/2001/XMLSchema#string

Marc Roller

http://www.w3.org/2001/XMLSchema#string

Martina Komor

http://www.w3.org/2001/XMLSchema#string

P304

105-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.23.7370

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Carsten Denkert

P577

2009-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38093710

http://www.w3.org/2001/XMLSchema#string

P698

19917869

http://www.w3.org/2001/XMLSchema#string

P921